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Abstract: Colorectal cancer is one of the most common cancer diagnoses and causes of mortality
worldwide. MicroRNAs are a class of small, non-coding regulatory RNAs that have shown strong
associations with colorectal cancer. Through the repression of target messenger RNAs, microRNAs
modulate many cellular pathways, such as those involved in cell proliferation, apoptosis, and
differentiation. The utilization of microRNAs has shown significant promise in the diagnosis and
prognosis of colorectal cancer, owing to their unique expression profile associations with cancer
types and malignancies. Moreover, microRNA therapeutics with mimics or antagonists show
great promise in preclinical studies, which encourages further development of their clinical use
for colorectal cancer patients. The unique ability of microRNAs to affect multiple downstream
pathways represents a novel approach for cancer therapy. Although still early in its development,
we believe that microRNAs can be used in the near future as biomarkers and therapeutic targets for
colorectal cancer.
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1. Introduction
Colorectal cancer (CRC) is currently the third most prevalent cancer type worldwide and is
a leading cause of cancer mortality for both men and women [1,2]. It was estimated that in
the United States in 2014 more than 130,000 cases of CRC were newly diagnosed and more than
50,000 deaths occurred due to this disease [2]. Despite the fact that the incidence rate of CRC has
been steadily declining, owing at least partially to improved diagnostic and therapeutic options, and
decreased societal risk factor exposure, the five-year survival rate for CRC is an unsatisfactory 64.9%,
highlighting the need for innovative detection and treatment applications [2–4].
MicroRNAs (miRNAs) are a class of small, non-coding RNA molecules that have been shown
to play an important role in the pathogenesis of several human diseases, including cancer [5]. These
RNA molecules are around 20–22 nucleotides in length and act to modulate the expression of other
genes [6]. Initially discovered as an important regulator in the development of C. elegans in 1993,
a surge of subsequent research has shown the importance of miRNAs in almost every aspect of
physiological and pathological conditions [7,8]. miRNAs exert their effects through complementarity
binding to the 31 untranslated region (UTR) of target mRNA sequences, resulting in the subsequent
degradation of mRNA or repression of mRNA translation into protein [8]. The biogenesis of miRNAs
involves a complex process including multiple stages. First, RNA polymerase II synthesizes primary
miRNA (pri-miRNA) in the nucleus, which undergoes cleavage by DROSHA and its cofactor DGCR8
to yield the premature miRNA strand (pre-miRNA). Pre-miRNA is then transported out of the
nucleus into cytoplasm via Exportin-5, where it undergoes further processing by DICER to yield
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the miRNA duplex. The duplex unwinds and the mature single-stand miRNA is incorporated into
RISC (RNA-induced silencing complex), through which it exerts its regulatory effects on mRNAs [8].
The functional significance these molecules may have is further illustrated by the fact that a single
miRNA can target multiple genes for repression, and multiple miRNAs may target the same gene [9].
Findings suggest that the total number of miRNAs in the human genome is 2588 [8]. Due to
the widespread importance miRNAs play in human developmental processes, it is not surprising
that they have important implications with regards to tumorigenesis. For example, it has been
shown that miR-15 and miR-16 are downregulated in chronic lymphocytic leukemia (CLL), let-7 is
downregulated in breast and lung cancers, miR-127 expression is silenced in bladder cancer, and
miR-21 is overexpressed in glioblastomas [5,10,11]. These are but a few examples, and numerous
other associations between miRNAs and human cancers have been found.
The strong correlation between miRNA expression and tumorigenesis has resulted in a great
deal of research looking into their potential utilization as cancer biomarkers and therapeutics.
Altered miRNA levels have also been associated with the maintenance of cancer stem cells
(CSCs), angiogenesis, and epithelial-mesenchymal transition (EMT), all of which contribute to
malignancy [12–14]. In this review article we describe the pathophysiology of miRNAs in CRC, point
to their potential uses as diagnostic and prognostic biomarkers, and describe their potential role in
innovative therapeutics. This paper represents a concise version for clinicians who will benefit from
a short yet comprehensive clinically relevant review. This is also the first review to our knowledge
that incorporates miRNAs showing importance in ulcerative colitis-associated CRC (UC-CRC).
2. MicroRNA (miRNA) Involvement in Colorectal Cancer (CRC)
The status of CRC in a patient spans the spectrum from benign adenoma or polyp to
malignant carcinoma. This disease progression involves several mechanisms, the most notably
being over-proliferation, loss of apoptotic regulation, acquisition of an invasive phenotype, increased
angiogenesis, and maintenance of CSCs (Figure 1). This progression typically involves upregulation
of numerous oncogenes, as well as downregulation of important tumor suppressor genes. The
first association between miRNAs and CRC was identified by Michael et al. in 2003, who found
decreased levels of miR-143 and miR-145 in CRC tissue compared to healthy tissue [6]. miRNAs may
take on an oncogenic or tumor-suppressive role in their regulation of pathways leading to cancer
formation. Oncogenic miRNAs, termed oncomiRs, typically target and downregulate endogenous
tumor-suppressor genes. Tumor-suppressive miRNAs, on the other hand, play an important role in
downregulating genes associated with growth and metastasis. The upregulation of oncomiRs and the
downregulation of tumor-suppressive miRNAs therefore have profound effects on the development
of cancer. An overview of current miRNAs associated with CRC is depicted in Tables 1–3.
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Table 1. Oncogenic miRNAs in CRC.
miRNA Target(s) Role in Cancer Reference
miR-21 PDCD4, TIAM1, SPRY2,PTEN, TGFBR2, CDC25A
Proliferation, Apoptosis, Invasion,
Migration, CSC maintenance [14–18]
miR-92a PTEN Proliferation, Invasion, EMT [19]
miR-96 TP53INP1, FOXO1, FOXO3A Proliferation [20]
miR-135a APC Proliferation [21]
miR-135b APC Proliferation [21]
miR-155 MLH1, MSH2, MSH6 DNA damage response [22]
miR-214 PTEN, PDLIM2 Inflammation [23]
miR-224 SMAD4 Metastasis [24]
PDCD4: programmed Cell Death 4; TIAM1: T-Cell Lymphoma Invasion And Metastasis 1; SPRY2:
Sprouty Homolog 2; PTEN: Phosphatase And Tensin Homolog; TGFBR2: Transforming Growth Factor, Beta
Receptor II; CDC25A: Cell Division Cycle 25A; TP53INP1: Tumor Protein P53 Inducible Nuclear Protein 1;
FOXO1: Forkhead Box O1; FOXO3A: Forkhead Box O3; APC: Adenomatous Polyposis Coli; MLH1: MutL
Homolog 1; MSH2: MutS Homolog 2; MSH6: MutS Homolog 6; PDLIM2: PDZ And LIM Domain 2;
SMAD4: SMAD Family Member 4.
Table 2. Tumor-suppressive miRNAs in CRC.
miRNA Target(s) Role in Cancer Reference
let-7 KRAS Proliferation [25]
miR-7 EGFR, RAF1 Proliferation [26]
miR-18a* KRAS Proliferation [27]
miR-26b TAF12, PTP4A1,CHFR, ALS2CR2
Proliferation, Apoptosis, Invasion,
Migration [28]
miR-27b VEGFC Proliferation, Angiogenesis [12]
miR-34a SIRT1 Apoptosis [29]
miR-101 SPHK1 Angiogenesis [30]
miR-126 VEGFA Angiogenesis [31]
miR-143 KRAS, IGF1R Proliferation [32,33]
miR-144 MTOR Proliferation [34]
miR-145 IRS1, NRAS, IGF1R Proliferation, Invasion, Migration,Angiogenesis [33,35]
miR-194 AKT2 Proliferation, Apoptosis, Invasion,Migration [36]
miR-195 BCL2 Apoptosis [37]
miR-320a CTNNB1 Proliferation [38]
miR-365 BCL2, CCND1 Apoptosis [39]
miR-491 BCLXL Apoptosis [40]
KRAS: Kirsten Rat Sarcoma Viral Oncogene Homolog; EGFR: Epidermal Growth Factor Receptor; RAF1:
Raf-1 Proto-Oncogene; TAF12: TAF12 RNA Polymerase II, TATA Box Binding Protein (TBP)-Associated
Factor, 20 kDa; PTP4A1: Protein Tyrosine Phosphatase Type IVA, Member 1; CHFR: Checkpoint With
Forkhead And Ring Finger Domains; ALS2CR2: STE20-Related Kinase Adaptor Beta; VEGFC: Vascular
Endothelial Growth Factor C; SIRT1: Sirtuin 1; SPHK1: Sphingosine Kinase 1; VEGFA: Vascular Endothelial
Growth Factor A; IGF1R: Insulin-Like Growth Factor 1 Receptor; MTOR: Mechanistic Target Of Rapamycin;
IRS1: Insulin Receptor Substrate 1; NRAS: Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog; AKT2:
V-Akt Murine Thymoma Viral Oncogene Homolog 2; BCL2: B-Cell CLL/Lymphoma 2; CTNNB1: Catenin
(Cadherin-Associated Protein), Beta 1, 88kDa; CCND1: Cyclin D1; BCLXL: BCL2-Like 1.
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Table 3. miRNAs associated with chemotherapy resistance/sensitization.
miR-17-5p PTEN Chemotherapy resistance, Migration [41]
miR-140 HDAC4 Chemotherapy resistance, Proliferation, CSC maintenance [42]
miR-192 TYMS Chemotherapy resistance, Proliferation [43]
miR-203 ATM Chemotherapy resistance [44]
miR-215 TYMS Chemotherapy resistance, Proliferation [43]
miR-222 ADAM17 Chemotherapy sensitization, Apoptosis [45]
miR-506 PPARA Chemotherapy resistance [46]
PTEN: Phosphatase And Tensin Homolog; HDAC4: Histone Deacetylase 4; TYMS: Thymidylate Synthetase;
ATM: Ataxia Telangiectasia Mutated; ADAM17: ADAM Metallopeptidase Domain 17; PPARA: Peroxisome
Proliferator-Activated Receptor Alpha.
Uncontrolled growth and proliferation are key components to the development of a primary
tumor. A major pathway associated with uncontrolled proliferation in CRC is the MAP kinase
pathway, involving proteins such as RAS, RAF, and ERK. Several miRNAs have been shown to
regulate proteins involved in this pathway. Let 7, miR-143, miR-18a* and miR-145, for example,
downregulate RAS and act as tumor-suppressive miRNAs in CRC [25,27,32,35]. The PI3K pathway
is another important signaling pathway associated with cell cycle regulation. Dysfunction of
its associated proteins, such as AKT and mTOR, is a key step in the development of colorectal
tumorigenesis. miR-194, as one example, has been found to repress AKT2 expression, decrease the
activity of the PI3K pathway, and in turn hinder proliferation [36]. miR-144 has also been found to
inhibit this pathway through negative regulation of mTOR [34]. Receptor tyrosine kinases (RTKs)
play a vital role in activating the signaling pathways involved in CRC development. miR-143 and
miR-145 are two miRNAs shown to have anti-tumor effects in CRC through their downregulation of
insulin-like growth factor 1 receptor (IGF1R) [33].
A necessary characteristic for uncontrolled cell growth involves the loss of appropriate apoptotic
control. Several miRNAs have been shown to be involved, and dysregulated, in apoptotic regulation
for CRC. miRNAs miR-195 and miR-491, for instance, have been found to promote apoptosis in
CRC cells through the targeting of B-Cell CLL/Lymphoma 2 (BCL2) and BCL2-Like 1 (BCLXL),
respectively [37,40]. Mutations in P53, a tumor-suppressor gene that is important in cell cycle
regulation and apoptosis, are common in CRC. miRNAs can negatively or positively influence the
activity of this protein. miR-96, for example, is found upregulated in CRC and is shown to target
p53 inducible nuclear protein 1 (TP53INP1), exerting downregulatory effects on p53 activity [20].
miR-34a, on the other hand, has been found to increase p53 activity through its inhibition of Sirtuin-1
(SIRT1) [29].
The development of certain types of CRC is also closely related to dysfunctions in mismatch
repair (MMR) enzymes. These enzymes act to repair mistakes in the genome brought about by
DNA synthesis. Dysfunctions in this process can unsurprisingly lead to mutations in protein-coding
genes, resulting in pathology, as well as introducing instability in repetitive stretches of DNA termed
microsatellites. Microsatellite instability (MSI) is a hallmark feature in defective MMR. Hereditary
non-polyposis colorectal cancer (HNPCC) is the most frequent hereditary form of CRC, and is caused
by mutations in MMR enzymes [47]. In addition, around 15% of sporadic CRC cases present with a
malfunctioning MMR process [47]. miRNAs have recently been shown to regulate genes associated
with MMR in CRC. miR-155, for example, targets hMLH1, hMSH2, and hMSH6, pivotal genes
involved in this process [22].
The acquisition of an invasive and migratory phenotype by cancer cells is a necessary step
in the development of metastasis. miR-21, which has been described as one of the most highly
upregulated miRNAs in CRC, downregulates several genes involved in controlling invasion and
migration, including PDCD4, TIAM1, SPRTY, and PTEN [15–18,48]. miR-224 has also recently
been found to enhance the metastasis of CRC through its modulation of SMAD4 [24]. EMT is an
important step associated with the development of an invasive phenotype, and miR-92a has been
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shown to promote this process through the suppression of E-cadherin [19]. Angiogenesis is another
key component of metastasis, and miR-27b has shown anti-angiogenic effects through its targeting of
vascular endothelial growth factor C (VEGFC) [12].
Alterations in the WNT signaling pathway are commonly found dysregulated in the initiation
and progression of CRC. Adenomatous polyposis coli (APC) inhibits WNT signaling via its
sequestration of beta-catenin, and has been implicated as one of the most commonly downregulated
genes in CRC [49]. The hereditary loss of this tumor-suppressor is characteristically seen in
Familial Adenomatous Polyposis (FAP), a genetic disorder that substantially increases the risk for the
development of CRC. Inactivation of APC in colon adenocarcinoma cells has been found associated
with increased levels of miR-135a/b [21]. In addition, miR-320a has been shown to directly target
beta-catenin, thereby decreasing the oncogenic capabilities of this pathway [38]. WNT signaling
has also shown close associations with the presence of CSCs in CRC [38]. Cancer stem cells have
the ability to repopulate a tumor population after treatment, and are vitally important with regards
to recurrence and therapeutic resistance. miR-21 has been shown to be critically involved in the
maintenance of CSC in CRC cells [14].
Chronic inflammatory disorders of the colon, such as ulcerative colitis and Crohn’s disease,
have shown to pose a greater risk for the development of CRC. The genetic alterations behind this
association play a pivotal role in the ultimate development of cancer. While the “classical” CRC
schema progresses from an adenoma to carcinoma, UC-CRC progresses through an intermediate
dysplasia stage. This unique development may culminate in cancer via several mechanisms, and
miRNAs have been shown to influence a number of these pathways. For example, miR-214 has been
shown to be increased in CRC associated with colitis, while no significant differences were found
in sporadic CRC and control specimens. In addition, miR-214 has been shown to indirectly activate
NF-κB, a potent pro-inflammatory molecule, through direct repression of PTEN and PDZ and LIM
domain2 (PDLIM2). This lends support for the role of miR-214 in the progression of CRC specifically
from colitis [23]. Researches suggest that miRNAs could be used to stratify the progression of
UC-CRC from UC. For instance, miR-375 shows a significant differential expression between UC
patients and UC-CRC patients [50]. In another study, a panel of five miRNAs (miR-193b, miR-373,
let-7e, miR-15b, miR-372) were shown to be differentially expressed in the development of UC-CRC
from UC and Crohn’s disease [51]. The level of miRNA could also be used to differentiate between
UC-CRC and sporadic CRC. Benderska et al. have found increased levels of miR-26b in the tissues
of two cohorts of patients with UC and UC-CRC, while decreased levels of miR-26b are typically
associated with sporadic CRC. It was further demonstrated that miR-26b likely contributes to the
progression of UC-CRC [52].
3. Diagnostic Potential of miRNAs in CRC
The five-year survival rate drops from around 90% for early-stage CRC patients to less than
15% for those with metastatic disease [4]. Early detection methods of screening and diagnosis are
therefore paramount to decreasing the mortality caused by CRC. Screening and diagnosis of CRC,
however, remains a significant challenge in today’s healthcare. According to the American College
of Gastroenterology, the currently preferred method of screening is colonoscopy [53]. Burdened by
an invasive, costly, uncomfortable procedure requiring significant bowel and dietary restrictions,
this method is not desirable for patients. The less invasive screening methods, such as fecal occult
blood test (FOBT), have also been found to cause discomfort and embarrassment among patients, as
well as having a suboptimal sensitivity [54,55]. The compliance rate for CRC screening in 2012 was
found to be around 65%, detailing the need for improved techniques [56]. The development of a
non-invasive, affordable, and highly specific and sensitive test would certainly improve the current
status of CRC detection.
In the past several years, miRNAs have been found to show incredible promise in offering
improved screening and diagnostic methods for both primary and metastatic CRC tumors. Firstly,
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the utility of miRNAs eliminates many of the negative characteristics associated with currently used
methods. The use of miRNAs in screening and diagnosis avoids the discomfort and invasiveness that
is typically associated with colonoscopy. In addition, dietary restrictions and stool preparations are
not warranted for plasma miRNAs, as they are with FOBT. Secondly, miRNAs show tissue specific
expression and are relatively stable, indicating their potential advantage as biomarkers [57,58].
Differential expression of miRNAs has been able to discriminate colon cancers from rectal cancers,
as well as MSI CRC from microsatellite stable (MSS) CRC [59,60]. miR-92a has been shown to have a
high sensitivity in the differentiation of proximal and distal CRC, and elevated miR-92a levels have
been able to distinguish CRC from inflammatory bowel disease (IBD) and gastric cancer (GC) [55,61].
Thirdly, miRNA expression profiles have been found to be highly accurate in predicting CRC [58].
Upregulated plasma levels of miR-92a, for example, have been shown to have a high specificity (70%)
and sensitivity (89%) in predicting CRC [55]. A separate study corroborated these results, and found
that miR-29a is also able to distinguish between CRC and healthy controls with a high specificity
(89.1%) and sensitivity (69%) [62].
miRNAs have also shown to remain at high levels in stool after 72 h, and fecal screening methods
are very reproducible [61]. Koga et al. have found that fecal miR-106a was able to predict CRC after
a false-negative prediction by FOBT [63]. Furthermore, fecal miR-221 has shown to be more specific
(74%) at predicting CRC than plasma levels of miR-221 (41%) [64].
Single miRNA expression levels are sometimes presented with conflicting results, and
combinations of miRNA levels have shown to be better predictors of CRC [65]. The combined use
of miR-92a and miR-29a yielded an improved specificity and sensitivity for detection of advanced
adenomas and CRC [62]. Yau et al. also found that the sensitivity and specificity of the fecal
miR-221 and miR-18a signature were higher in predicting CRC than the use of either miRNA
independently [64].
Metastasis plays a prominent role in mortality due to CRC. As stated previously, miRNAs play
an important role in the development of metastatic features of tumors, and it follows that these
signatures can also serve as diagnostic biomarkers. Hur.et al. have found a miRNA expression profile
consisting of let-7i, miR-10b, and miR-885-5p that is specific for CRC metastasis [66]. miR-592 and
552 levels could also distinguish between primary lung cancer and lung metastasis secondary to
CRC [67]. Carcinoembryonic antigen (CEA) is a currently used biomarker for CRC metastasis, and
Cheng et al. have shown that miR-141 may be used in conjunction with CEA to increase its predictive
capabilities [68,69].
4. Prognostic Implications of miRNAs in CRC
In addition to their potential uses in screening and diagnosis, miRNAs have shown promise as
valuable markers of CRC, being able to predict recurrence, survival, and drug response.
Post-surgical recurrence occurs in about 45% of CRC patients, resulting in a worsened
prognosis [70]. The ability to accurately predict recurrence risk would be very beneficial in the
decision to treat a patient with adjuvant therapy after surgical resection. It has been found that certain
miRNAs may serve as better prognostic indicators than currently used factors. For example, miR-200c
was found to be a better predictor of relapse in stage II and III CRC patients than either CEA levels
or pathological staging [71].
Overall survival (OS) and progression-free survival (PFS) often go hand in hand with relapse.
As expected, miRNAs can provide valuable information with regards to this aspect of CRC as
well. It has been found, for example, that increased levels of miR-126 are significantly associated
with a longer PFS in CRC patients [72]. Certain polymorphisms within miRNAs have also been
shown to serve as potential prognostic markers. For example, Xing et al. found single-nucleotide
polymorphisms (SNPs) in pre-miR-423 and pre-miR-608 that were significant predictors of OS and
PFS in CRC [73].
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Perhaps one of the most important prognostic applications of miRNAs in CRC is their ability to
predict a therapeutic response to certain chemotherapy agents. Chemotherapy remains a primary
treatment option for patients with CRC, and the development of resistance remains a significant
obstacle. Chemotherapy resistance is often multifactorial, and may involve maintenance of CSCs,
increased ability to repair DNA damage, and reduced apoptosis. miRNAs are intimately involved in
these processes and therefore help to modulate the development of resistance.
Most chemotherapeutic regimens for CRC consist of a combination of several different agents.
One commonly used regimen is composed of oxaliplatin, 5-fluorouracil (5-FU), and leucovorin
(FOLFOX) [74]. Several miRNAs have been shown to act as markers that have the ability to predict
a patient's response to these agents. This predictive information would help prevent unnecessary
treatment for some patients who otherwise would not benefit, as well as providing a better outcome
for those patients who are predicted to be responsive. miR-625-3p and miR-203 for example, were
found to be upregulated in CRC cells resistant to oxaliplatin [44,75]. Upregulation of miR-17-5p
has been found to be associated with resistance to 5-FU in CRC, possibly through its repression of
PTEN [41]. Other miRNAs, such as miR-192 and miR-215, have been shown to target thymidylate
synthase (TYMS), a potential target of 5-FU. Surprisingly, however, these miRNAs seemed to increase
resistance to 5-FU, rather than improving the drug’s efficacy [43]. This is thought to be due to
the complex actions of miR-192 and miR-215. Polymorphisms within miRNAs have also shown
prognostic value in determining drug response. For example, variants in miR-291-1, miR-608,
miR-26a-1, and miR-100 have shown associations with response to chemotherapy treatment [76,77].
The effect of certain miRNAs on chemotherapy resistance has also been related to the patient’s
p53 status. In patients with a mutated p53, it was shown that inhibition of miR-520g resulted in
an improved sensitivity to 5-FU [78]. It was also found by Song et al. that chemoresistance due
to an upregulation of miR-140 in CRC cells following methotrexate treatment was dependent on a
functional p53 protein [42].
Anti-EGFR monoclonal antibodies, such as cetuximab, belong to another class of therapeutic
agents utilized for CRC treatment [79]. It is widely known that patients with a mutated KRAS
gene have a poor response to these treatments, and considering the strong association between
miRNAs and KRAS signaling, it is not surprising that certain miRNAs have prognostic value for
predicting their therapeutic response. It has been found that low levels of miR-181a, for example,
may be associated with a worse prognosis in patients treated with anti-EGFR therapy [79]. miR-7 and
the miR-99a/let-7c/miR-125b signature may also play an important role in regulating CRC patient
responses to anti-EGFR therapies [26,80].
Additional classes of chemotherapeutic drugs have also shown differing sensitivities to CRC
cells due to altered levels of miRNAs. Upregulation of miR-101, for example, has been shown to
increase the sensitivity of CRC cells to microtubule inhibitors, such as paclitaxel, and anthracyclines,
such as doxorubicin [30]. Tong et al. have also shown a correlation between hydroxycamptothecin
resistance, which is a topoisomerase I inhibitor utilized in the drug irinotecan, and upregulated
miR-506 expression [46]. In addition, miR-144 has shown promise in predicting CRC cell
susceptibility to rapamycin [34].
Radiation therapy has been shown to be an effective adjuvant therapy in patients with rectal
cancer [81]. Similar to chemotherapy, radiotherapy sensitivity has been shown to be associated with
miRNA levels. Yang et al., for example, have recently found an association between levels of miR-100
and the development of radioresistance in CRC cells [82].
5. Targeting miRNAs for CRC Therapy
The intimate involvement miRNAs have in the pathophysiology of CRC lends significant
support for their utilization in novel therapeutics. As mentioned previously, several currently used
chemotherapeutic drugs show an altered efficacy depending on the expression levels of certain
miRNAs. It has been suggested that this knowledge can be utilized through introduction of miRNA
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mimetics or inhibitors to improve drug response. For example, miR-143 has been found to increase
CRC cell sensitivity to 5-FU [83]. It is therefore plausible that a combined therapy of 5-FU and
a miR-143 mimetic would increase a patient's positive prognosis. Functional studies have also
demonstrated that induction of miR-365 in CRC cells enhanced apoptosis mediated by 5-FU [39].
Furthermore, it has been found that the downregulation of chemoresistant genes, such as SIRT-1,
can be achieved through upregulation of their regulator miRNAs, such as miR-34a, resulting in an
improved drug response [31].
Several miRNAs have also shown promise in combination therapy with anti-EGFR CRC
therapeutics. miR-147, for example, has been shown to increase CRC sensitivity to gefitinib after
induction of mesenchymal-epithelial transition (MET) [84]. While anti-EGFR treatment is not effective
in patients with a mutated KRAS protein, Ruzzo et al. found that upregulation of let-7a may rescue
anti-EGFR sensitivity in such CRC patients [85].
With regards to additional classes of chemotherapeutics, miR-192 has shown promise as a
sensitizer of CRC cells to methotrexate. Due to its pleomorphic effects, the combination of
miR-192 with methotrexate has shown greater efficacy than alternative combinatorial treatments [86].
Furthermore, ADAM-17, a protein potentially involved in multi-drug resistance (MDR) in CRC cells,
is regulated by miR-222, lending support for its utilization in combination therapy for CRC [45].
It is plausible to consider that the restoration of downregulated tumor-suppressor miRNAs
in CRC patients may provide a significant therapeutic benefit. Many miRNAs have shown
anti-tumorigenic effects, and it would seem appropriate to base potential therapies on miRNAs
involved in multiple tumorigenic pathways. miR-26b, for example, has been shown to target several
different oncogenic genes in CRC (Table 2). Furthermore, research in xenograft models suggests that
miR-26b mimics are non-toxic and may serve as potential treatments in humans [28]. miR-21, on
the other hand, has been described as a powerful oncogenic miRNA, contributing to carcinogenesis
via several different mechanisms (Table 1). Downregulation of miR-21 has been suggested as a
therapeutic target based on its widespread functional associations with CRC.
miRNAs have also shown promise in the development of drugs targeting specific novel
pathways associated with cancer. Anti-angiogenic therapies, for example, are being used more
frequently in CRC treatment. Bevacizumab is one currently approved monoclonal antibody that has
anti-angiogenic effects by targeting VEGF [87]. miR-126 has also shown therapeutic potential in CRC
through its targeting of VEGFA and its subsequent regulation of angiogenesis [31].
In attempting to downregulate an oncogenic or drug resistance-promoting miRNA, one would
typically use small molecule inhibitors of the target miRNA, termed antagomiRs [88]. These
agents act through high affinity binding to the target miRNA strand, resulting in its degradation
or repression. One potential complication with antagomiR use, however, is their ability to bind to
unintended RNAs, causing unwanted side effects [88].
miRNA replacement therapy, on the other hand, attempts to increase the effects of
tumor-suppressive and drug sensitizing miRNAs through introduction of analogous miRNA
molecules. This can be done through a gene replacement therapy similar to that utilized for
small interfering RNAs (siRNAs), which is thought to present fewer difficulties than gene therapy
with protein-coding genes. Innovative delivery methods utilizing liposomal and polymerase-based
techniques are currently being explored. It is also believed that these mimics will produce fewer
negative side effects than typical gene replacement treatment. Current therapies utilizing miR-34a
and let-7 mimics, both of which have tumor-suppressor roles in CRC, have shown therapeutic
efficacy in mouse models of lung and prostate cancers [88]. Excitingly, the first clinical trial utilizing
miRNAs in cancer treatment began in 2013 with MRX34, a liposomal-based mimic of miR-34 to be
used in patients with advanced hepatocellular carcinoma [89]. While the theoretical applications
of miRNA therapy in CRC is very promising, its delivery and practical applications still present
significant challenges. Suboptimal pharmacokinetic properties represent the need for increased
stability, improved uptake, and more efficient clearance for these novel drugs [88].
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6. Challenges and Obstacles
While research suggests that the use of miRNAs as potential biomarkers in CRC is promising,
there are considerable challenges hindering the clinical application of miRNAs for CRC diagnostic or
prognostic purposes. The practical way of using miRNAs as clinically relevant biomarkers for CRC
is to measure miRNA levels in stool or in body fluid such as plasma. However, technically this can be
very challenging, largely due to lack of standardization in the experimental approaches. For instance,
plasma collection time point, plasma collection procedures, storage conditions, transportation
methods, detection method, and normalizations could all affect the final miRNA detection and
analysis. This is further complicated by recent findings of enrichment of miRNAs in exosomes,
which can be separated from the serum by using ultracentrifugation methods. Therefore, different
protocols used in the plasma RNA extraction will inevitably lead to discrepancies in the research
findings by different groups. Standard operation procedures from sample collection to final analysis,
which are still lacking right now, are key for successful translation of miRNA discovery into clinical
settings. In addition, oligonucleotide-based miRNA therapeutics need to overcome challenges related
to uptake efficiency, tissue and tumor specificity, unintended side effects, and a more effective and
safe delivery system.
Another obstacle impeding the application of miRNA knowledge into clinical use lies within the
inherent characteristics of miRNA molecules. The expression and function of miRNAs are fine-tuned,
and largely dependent on the cellular context. One miRNA could have multiple targets, but these
targets may not all be regulated by the miRNA in every circumstance. How a miRNA targets one
target but not another in a specific context remains to be discovered. Until these questions can
be clearly answered, utilizing miRNAs as biological functional surrogates will be ambiguous, and
seriously hinder their use as clinical biomarkers and therapeutics.
7. Conclusions
Since the initial discovery of their associations with cancer in 2002, the amount of research
and knowledge involving miRNAs has exploded. While the clinical use of miRNAs still faces
many challenges, we believe this area of research holds significant implications with regards to
improvements in CRC morbidity and mortality. CRC is characterized by genetic alterations, and
miRNAs have proven vital in the regulation of genetic expression. As this paper has attempted
to convey, an enormous amount of information detailing the specific roles miRNAs play in
CRC pathology currently exists, and this knowledge base continues to expand. We believe that
with improved understanding of miRNA biology, delivery system innovations, and detection
methodologies, we will see the utility of miRNA use in the diagnosis and treatment of CRC patients
in the near future. Harnessing this current and future information can potentially change the way
CRC is diagnosed and treated, improving the livelihood of millions of people worldwide.
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